# Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

> **NCT07318597** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 99 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** REGN13335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07318597
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2028-03-08
- **Final completion:** 2028-09-27
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318597, "Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07318597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*